Current Issues

Regular Industry Development Updates, Opinions and Talking Points relating to Manufacturing, the Supply Chain and Logistics.

Sound Technology Could be the Answer for Pharmaceutical Companies Weathering the Brexit Regulatory Storm

01-Dec-2017
Sound Technology Could be the Answer for Pharmaceutical Companies Weathering the Brexit Regulatory Storm
The Brexit referendum of June 2016 seems a long time ago now, but Britain is yet to fully understand the consequences of what our exit from the European Union will mean and the ramifications it will have on our businesses and manufacturing sectors. The pharma industry is one such sector that is destined to be affected greatly. Just this summer the European Medicines Agency (EMA) and the European Commission jointly published regulatory guidance that said drugs made in Britain will be treated as imports by the EU in the event of a “hard” Brexit and that the life sciences sector will face a series of new regulatory obligations as a result.

The paper is a stark reminder of the potential disruption UK-based companies could face if Britain and the EU struggle to reach agreements on regulation of various areas in the economy. However, in reality, many issues are still up in the air after only a few rounds of negotiation talks. Yet on a practical level, the EMA has already said that the agency—currently based in London’s Docklands—should find a new home for its 900 staff in an EU country.

This issue has rightly thrust the regulation of the pharmaceutical sector in the UK into the spotlight as a key point to be negotiated in the run-up to Brexit. But with so many ‘known unknowns’ what can companies operating in the industry do to prepare? And does technology now have an even more important role to play in weathering the Brexit storm?

Industry impact
Pharmaceuticals are a hugely important industry for the UK, creating thousands of jobs and generating over 10% of the country’s gross domestic product. The industry is increasingly voicing its worries about the post-Brexit future. So much so that, the chief Executive of GlaxoSmithKline, Britain’s largest drug manufacturer employing 17,000 UK staff, warned the industry needed time to adjust to the coming disruption.

And in response to the EMA paper, the Association of the British Pharmaceutical Industry (ABPI) recently warned of a “crisis” scenario of drastically reduced access to European markets and hundreds of millions of pounds of restructuring costs unless a swift regulatory deal can be struck with Brussels.

With the EMA regulating medicine for the entire EU market—which in turn accounts for a quarter of all global pharmaceutical sales—the sheer size of the potential impact of the UK’s withdrawal is undoubtedly worrying for the sector’s businesses. The process is likely to affect every stage of drug development and commercialisation, from the earliest stages of research to pricing and distribution throughout the world.

Nevertheless, the good news is that the industry already has experience of dealing with fast-changing operating environments. Like many other sectors, the pharmaceutical industry today is changing due to increased competition and demands for efficiency, alongside the development of a myriad of international regulations and supply chain complexity.

Weathering the storm
The companies that learn to adapt to new regulations are best placed to take advantage of new market opportunities and drive business growth. So, what steps should the sector be taking now to prepare for upcoming regulatory changes?

With so many unknowns, one thing is for sure—pharma companies must continue to ensure that they remain compliant with the regulations that control the market every step of the way, whether they are EU directives or the ensuing UK rulings post-Brexit.

Failure to build-in compliance to every part of a company’s processes can have a significant impact on a business. For example, if product re-testing needs to be done, it can lead to manufacturing downtime, increased manufacturing costs, product quarantines, increased waste, and product shortages. That’s why ensuring compliance—whatever that may look like in the future—must remain a priority.

During the global financial crisis, those businesses that were able to best weather the storm brought about by international economic uncertainty were those who had the right processes and procedures in place to respond quickly to the changing nature of the markets. The issue of post-Brexit uncertainty is no different.

Technology investments
In this context, technologies such as enterprise resource planning (ERP) software can add real value to pharmaceutical companies by providing a holistic view of a company’s operations and access to real time data that ensures decisions can be made to overcome potential challenges that lie ahead.

Software can automate processes and reports to make compliance much easier and businesses more efficient and better able to adapt to change. For example, post-Brexit UK businesses will have the opportunity to open up trade with new countries around the world. In order to conduct business globally, enterprise business software enables compliance with local laws, satisfies international security measures and meets the many different local and regional documentation requirements. It can also provide manufacturers with greater traceability in their business processes. ERP offers technology that will verify and track each component in the production process and assist in any needed recall actions necessary to remain compliant in all territories.

Updating legacy systems and replacing multiple disparate solutions with one, end-to-end system provides an opportunity to create a robust framework to support the various demands of local certification and audit requirements. This can include comprehensive change logs with time and date stamp capability, business process management that can deliver approval criteria for key processes as well as support for electronic signatures and Electronic Batch Records to meet the requirements of CFR 21 part 11.

Despite the uncertainty surrounding Brexit, international business will, of course, still carry on and UK pharmaceutical businesses will be looking for growth opportunities. Agile and responsive ERP technology can help pharmaceutical businesses weather turbulent times and be equipped to grow their businesses whatever regulations are placed in their way.

With the Intelligent Enterprise, SAP Creates “A Completely Different Kind of Flexibility”
3 days ago
The supply chain is only as strong as its weakest link
4 days ago
‘A revolution happened in the way we buy services last week – and no one has noticed!’
5 days ago
Hot Topics at GS1 Connect? Labeling, Blockchain and More
5 days ago
Retailers must Embrace Change
6 days ago
Labeling Solutions That Bridge Islands of Data
1 week ago
My Journey to the World’s Most Important Gathering of Supply Chain Leaders
1 week ago
Workforce of the Future
2 weeks ago
Securing your supply chain against political uncertainty
2 weeks ago
On-demand warehousing could help retailers score big this summer
2 weeks ago
Half of organisations set for major procurement and supply chain AI investment within two years
2 weeks ago
Brexit, the weather & online shopping: How Britain’s favourite conversations are shaping supply chains
2 weeks ago
The Road to Regulatory Compliance for Your Supply Chain Labeling
2 weeks ago
The War on Packaging
3 weeks ago
Five data dramas that keep your CIO awake at night
4 weeks ago
As sales fall new report finds many department stores’ websites suffer from clunky integration and poor delive
1 month ago
Got Your Surfboards Ready to Master the Wave of Digitalization?
1 month ago
TrustArc to Offer IAPP Privacy Core® GDPR Training to Address Compliance Requirements
1 month ago
The Market has never been Stronger for Horizontal and Vertical API Platforms
1 month ago
Selecting the best Transport Management System - One of the most important logistics decisions you’ll make
1 month ago
“Digital Transformation” and Supply Chain Planning
1 month ago
Coolest Advice for Making Blockbuster IoT Devices?
1 month ago
The Fall of ‘Made in China’
1 month ago
How can artificial intelligence help the food industry?
1 month ago
Streamlining Operations With Waveless Picking
1 month ago
Creating a common standard for the fashion supply chain…
1 month ago
5 Steps to Improve Your Business’s Supply Chain
1 month ago
Procurement is joining the dots with technology to achieve greater strategic benefits
1 month ago
Don’t get red-carded shipping World Cup items into Russia
1 month ago
Trash talk: how waste management could become an engine for business growth
1 month ago
Could consumers drive a business tech revolution?
2 months ago
Jungheinrich Opinion: The Connected Engineer
2 months ago
Debunking the myths of the Hybrid Cloud
2 months ago
How to Future-Proof a Retail Business
2 months ago
How Enterprise Label Solutions Streamline Supply Chain Management
2 months ago
Ignorance 4.0? UK manufacturing and engineering competitiveness at risk from lack of knowledge
2 months ago
Untangling S&OP and S&OE
2 months ago
The ghosts of retail past, present and future
2 months ago
How to safeguard customer loyalty using digital platforms
2 months ago
The last mile starts with a single step
2 months ago
How citizen developers can speed up business app development
2 months ago
RFID – The missing link in customer insight
2 months ago
Turning blockchain into a real supply chain advantage
2 months ago
Achieving a Sustainability-Centric Retail Model
2 months ago
Gartner Says Global IT Spending to Grow 6.2 Per Cent in 2018
2 months ago
Monster opportunity: the Vampire Economy will take wings this year with late night deliveries
2 months ago
Falsified Medicines Directive: What are the practical considerations for wholesalers and Logistics Partners?
2 months ago
UK manufacturing sees solid growth in March
2 months ago
Elevating IT in financial services
2 months ago